The pharmaceutical company could soon resume its long lasting bullish trend.

The group has strong fundamentals and benefits from qualitative Surperformance ratings. Estimated sales from Thomson Reuters consensus are encouraging. Debt is decreasing rapidly and the 2013 leverage is reducing at 0.58 from 2.30 in 2011. Moreover, EPS for the next two years have been significantly revised upward, a YoY increase of 26%.

From a technical viewpoint, the security is trading in a bullish trend in the short and the long term but this trend was stopped at the GBp 1678 resistance. Lately, the share has come back near this important level. Increasing moving averages on all time scale let think that when the stock will breakout this resistance, the bullish trend will resume.

Therefore, taking into account the strong fundamentals and technical patterns; it seems opportune to take a long position after passing the GBp 1678 resistance. The target price is the trend line near GBp 1750. A stop loss will be placed under the entry points.